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CObjective: To assess the quality of pharmacoeconomic evaluations
(PEs) submitted with new drug applications for reimbursement and to
investigate the role of PEs for coverage decisions in Korea.
Methods: Forty-seven PEs that were submitted by pharmaceutical
companies for coverage decisions between June 2005 and December
2009 were included in this study. To assess their appropriateness with
regard to the PE guidelines, we used the Health Insurance Review and
Assessment services (HIRA) checklist consisting of 20 items based on
the PE guidelines. We also evaluated the results for coverage decisions,
as “recommended,” “recommended with restricted use,” or “not rec-
ommended,” based on the incremental cost-effectiveness ratio and the
range of uncertainty. Results: On average, 14 of the 20 items on the
IRA checklist were fulfilled (70.9%, range 35.0%–100%). The compli-
nce rate for the following items was above 70%: presentation of per-
pectives and evaluation methods, a sufficient time horizon, and ap-
ropriateness of comparators and health outcomes. The compliance
ate for the following items was below 70%: omission of objectives for
he study, inappropriate target population, unclear selection process O
ith re
Heal
al So
doi:10.1016/j.jval.2011.11.026or effectiveness and cost, inappropriate cost estimation, insufficient
ustification of generalizability, and description of study limitations.
he range of incremental cost-effectiveness ratios per quality-ad-
usted life-years of PEs from a societal perspective varied from dom-
nant to 59K USD (n  13): it consisted of dominant to 28K USD for
recommended” submissions (n  6), 8K to 20K USD for “recom-
ended with restricted use” submissions (n  4), and 13K to 59K for
not recommended” ones (n 3). Conclusions: Our study showed that
ost PEs in this study have reached an adequate level for coverage
ecisions. Overall barriers associated with a lack of relevant evidence
ould account for the low compliance rate with specific items in the PE
uidelines. PEs with good quality submitted for coverage decisions
ave played an important role for selecting cost-effective drugs.
eywords: drug reimbursement, Korea, pharmacoeconomic evaluations,
uality assessment.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Recently, expenditures on pharmaceuticals are the fastest
growing sector within health care. In an attempt to control ex-
penditures and to assess the value of new drugs, economic eval-
uations are increasingly used by several bodies such as govern-
ment agencies and managed care groups that determine
whether new pharmaceutical treatments should be listed in
public formularies [1– 6].
Although total spending on health as a share of the gross do-
mestic product (GDP) in Korea is low (6.4% of the GDP in 2006), real
health expenditures per capita have increased rapidly over the
past decade. The rise in pharmaceutical spending has been one of
the factors behind the increase in total health-care spending in
Korea [7]. In 2006, spending on pharmaceuticals accounted for
25.4% of total health-care spending, one of the highest proportions
in the Organization for Economic Co-Operation and Development
area and well above its average of 17.3% [8]. In addition, compared
with other countries such as Switzerland, Canada, and Sweden,
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Published by Elsevier Inc.which are in a positive list system, our previous pharmaceutical
benefit schedule in the negative list system consisted of approxi-
mately 20,000 drugs, which was huge [9–11]. Under the negative
list system, almost all the drugs that were approved by the Korean
Food and Drug Administration were automatically listed for reim-
bursement, and the cost-effectiveness of new drugs was rarely
taken into account in coverage decisions. Therefore, it was hard to
manage the National Health Insurance reimbursement list effi-
ciently, and nobody knew the monetary value of the listed drugs.
With growing attention to pharmaceutical spending, the Ko-
rean government implemented the Health Care System Reform
Act effective December 29, 2006. The goal was to convert the phar-
maceutical benefit schedule to a positive list system that selects
drugs that are both therapeutically effective and cost-effective.
This was done in accordance with a rationalization plan for the
sustainability of the National Health Insurance. To ensure credi-
bility and objectivity in pharmaceutical reimbursement decision
making, the government delegated authority to the HIRA, an in-
dependent and specialized agency for reviewing and evaluating
health-care technologies. HIRA is responsible for the assessment
gard to the content of this article.
th Insurance Review and Assessment Services, 1451-34 Seocho3-
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ment restrictions of all submitted drugs by considering the effi-
ciency of drugs and the severity of the disease. In the process of
decision making, internal HIRA staff members carefully review
submitted dossiers as well as additional data obtained from a
comprehensive search, claims data, and experts’ opinion. Finally,
HIRA is advised by the Drug Benefit Coverage Assessment Com-
mittee, which is composed of 18 multidisciplinary members with
expertise in medical practice, clinical pharmacology, health eco-
nomics, pharmacoepidemiology, and other disciplines. According
to the Act, pharmaceutical companies that want their new drugs
to be listed on the National Health Insurance reimbursement list
can, to justify their value for reimbursement, voluntarily submit
dossiers following a prespecified form. Pharmacoeconomic evalu-
ations (PEs) were mandatorily requested for drugs, especially ones
superior to the comparator drug in terms of clinical benefits but
costing more, to justify the higher cost corresponding to the im-
proved effectiveness of drugs. HIRA published the draft guideline
in 2005 and the official guidelines in 2006 for PEs. The guidelines
assist companies in preparing documents to justify the cost-effec-
tiveness of drugs that can be listed in the national drug formulary
[12,13].
Although several countries, such as Canada and Australia,
have implemented their own PE guidelines over the past decade,
divergence from the guidelines was frequently reported [14–19].
tems for which they were incompliant with the guidelines in the
ther countries were uncertainty about clinical effectiveness [1],
cost estimation [16], and transparency of the methods [14,15,20].
efore HIRA published the PE guidelines, there have also been
imilar issues for PEs that were published in Korean journals [2].
his study was conducted to evaluate the current state of the PEs
hat were submitted for coverage decisions by assessing the qual-
Table 1 – The HIRA checklist for quality assessment of pha
decisions.
Topic
Objectives Is the object of the
Perspective Are the perspectiv
Type of evaluation Is the evaluating m
Target population Is there consisten
Time horizon Does the analytic
Comparator Are the reasons fo
Is the choice of co
Data source Is the methodolog
Clinical benefit estimation Is the clinical evid
reimbursed?
Cost estimation Is the methodolog
disaggregate wa
Is the measureme
Health outcomes Are the health out
Discounting Has the discount r
Model analysis Are the choice of e
and justified?
Uncertainty evaluation Is sensitivity analy
uncertainty?
Is uncertainty full
Generalizability Are the included d
Results Has an increment
Budget impact Has the financial i
Others Do the authors ex
HIRA, Health Insurance Review and Assessment Services.
* Questions, which consisted of 20 items, were developed for asse
guidelines that were developed in Korea for assisting in preparingty level of the PEs since the development of the PE guidelines. Inddition, we investigated the role of the PEs by evaluating the
esults for coverage decisions in Korea.
Methods
We assessed PEs that were submitted by pharmaceutical com-
panies for coverage decisions and completed for decision mak-
ing by HIRA between June 2005, when the first PE was evaluated,
and December 2009. We analyzed the completed HIRA check-
lists and HIRA decision documents for submitted PEs and con-
fidential dossiers that were finalized by the pharmaceutical
companies according to HIRA’s review process. All data ex-
tracted for this study were verified retrospectively by indepen-
dent internal reviewers.
To assess the quality and identify the general features of the
PEs, HIRA used the HIRA quality assessment checklist (Table 1)
based on the PE guidelines developed in Korea. The checklist was
composed of 15 topics and 20 subordinate items that allowed a
choice of three responses: “yes,” “no,” or “not applicable.” The
compliance rate of each submission was calculated by dividing the
number of “yes” responses by the total number of items on the
HIRA checklist. The compliance rate of the individual items was
calculated by dividing the number of submissions with “yes” re-
sponses by the total number of applicable submissions. We also
evaluated the quality of the PEs by using the Quality of Health
Economic Studies (QHES) instrument to make comparisons with
other sites. The QHES checklist contains 16 items and scores each
as 0 (lowest quality) to 100 (highest quality) with weighted point
values [21]. Mean compliance rates of both checklists and the
QHES score were calculated by giving default points on inapplica-
ble topics.
We assessed the compliance rates of all submissions accord-
coeconomic evaluations submitted for coverage
Questions*
y presented in a clear and specific manner?
he analysis and reasons for its selection stated?
d presented and appropriate?
ween evaluated and reimbursed patients?
on allow time for all relevant and important outcomes?
selection of comparator(s) mentioned?
ator(s) appropriate?
searching and abstracting data clearly stated?
unbiased and obtained from the target patients expected to be
estimating quantities and unit costs described in a clear and
relative costs appropriate?
measures and scales valid and reliable?
een used for both costs and effects?
mic model, main assumptions, and limitations of the study stated
erformed for uncertainty of all assumptions and variables incurring
dled to cover the range of assumptions?
ources proper to generalize the applicable population?
lysis been made?
t been analyzed?
y discuss the direction and magnitude of potential biases?
appropriateness according to the pharmacoeconomic evaluation
acoeconomic evaluations for coverage decisions.rma
stud
e of t
etho
cy bet
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r the
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y?
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the results of coverage decisions based on the incremental cost-
effectiveness ratio (ICER) and the range of uncertainty. Sub-
group analysis was done for the PEs that were submitted after
the implementation of the new system, because these analyses
were mandatory documents needed to justify the cost-effec-
tiveness of drugs subsequent to the reform of the pharmaceu-
tical benefit schedule. Descriptive analysis and the Kurskal-
Wallis test were used to identify any significant differences in
compliance rates with regard to the coverage decisions.
Results
General characteristics
Overall, 51 PEs were submitted for coverage decisions. Among
them, four submissions were withdrawn by pharmaceutical com-
panies before the decision-making process, and these were ex-
cluded. The remaining 47 were included in our study, and their
general features are presented in Table 2.
Perspective
The PE guidelines request that PEs should present the perspec-
tive of the analysis and reasons for its selection, and suggest
carrying it out from a societal perspective for the base-case
analysis. Of the 47 submissions, 45 (96%) stated the adopted
perspectives: 34 (72%) were evaluated from a societal perspec-
tive and the other 11 (23%) were analyzed only from a public
payer perspective.
Evaluation methods
Of all submissions, 17 (36%) used cost-minimization analysis, 13 (28%)
used cost-effectiveness analysis, and 17(36%) used cost-utility analysis.
Time horizon
The PE guidelines recommend that the time horizon should be
enough to identify the major health outcome; however, only 33
submissions (70%) were evaluated with analytic horizon to allow
time for all relevant outcomes. Of the 47 submissions, 19 (41%)
were analyzed for a short period of time (1 year), 18 (38%) for 1 to
10 years, and 8 (17%) for a period of more than 10 years.
Clinical data sources
The PE guidelines suggest choosing unbiased evidence, such as
randomized controlled trials (RCTs) involving the target patients
expected to be reimbursed. Of the 47 submissions, 30 (64%) were
evaluated by using RCTs, directly comparing the intervention with
appropriate comparators; 15 (32%) included RCTs comparing the
intervention with inappropriate comparators; and 2 (4%) did not
include any RCT evidence in their analysis.
Economic data sources
The PE guidelines recommend using national utilization and
unit cost of resources and presenting them in a disaggregate
way. Domestic resources for cost data, however, were used in 28
submissions (60%). This consisted of national statistics (n  10,
21%), hospital chart review (n  2, 4%), market research data (n
4, 9%), and clinical expert opinion (n 12, 26%). In some cases,
owever, cost resources from foreign countries were used with-
ut mentioning the applicability and transferability to domestic
ircumstances (n 9, 19%). Of the 47 submissions, 14 (30%) were
ard to evaluate because references were unclear.Modeling estimation
The PE guidelines request that the analyses present the reason
and justification for using a modeling approach as well as as-
Table 2 – General characteristics of the
pharmacoeconomic evaluations assessed by HIRA.
Item n %
Perspectives evaluated
Societal 34 72
Payer 11 23
Unclear* 2 4
Type of economic evaluation
CMA 17 36
CEA 13 28
CUA 17 36
Time horizon
6 mo 13 28
6 mo–1 y 6 13
1–10 y 18 38
Over 10 y 8 17
Not specified 2 4
Data source
Effectiveness
No RCT evidence 2 4
RCT with appropriate comparator(s)† 30 64
RCT with inappropriate comparator(s) 15 32
Cost‡
National statistics data 10 21
Hospital chart review 2 4
Market research 4 9
Expert opinion 12 26
Data from other PE studies 2 4
Cost data from foreign countries 7 15
Unclear 14 30
Type of health outcomes
QALY 17 36
Life year saved 6 13
Intermediate (surrogate) outcomes 24 51
Modeling estimation§
Decision tree 9 45
Markov analysis 11 55
Evaluation of uncertainty
Deterministic sensitivity analysis 34 72
Probabilistic sensitivity analysis 3 7
None 10 21
n  Number of relevant submissions.
%  Proportions were calculated by dividing the number of relevant
submissions on the individual items by the total number of submis-
sions.
CEA, cost-effectiveness analysis; CMA, cost minimization analysis;
CUA, cost-utility analysis; HIRA, Health Insurance Review and As-
sessment Services; PE, pharmacoeconomic evaluation; QALY, qual-
ity-adjusted life-year; RCT, randomized controlled trial.
* Perspectives evaluated were unclear to identify health outcome
and cost.
† Including placebo treatment if the submitted drugs have no alter-
native treatment.
‡ The items were counted more than once.
§ Twenty submissions with modeling were submitted (11 submis-
sions after the introduction of a positive list system). Proportions
were calculated by dividing the number of relevant submissions
by the total number of applicable submissions assessed with sub-
mitted models.sumptions and limitations of the adapted model when such an
w
a
f the
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sizing the results of several trials, or for other objectives. Mod-
eling approaches were used in 20 submissions (43%), which con-
sisted of Markov models (n  11, 55%) and decision models
(n  9, 45%).
Uncertainty
Conducting sensitivity analysis with a sufficient range to cover
uncertainty is recommended in the PE guidelines. Sensitivity anal-
ysis was done for 37 of the 47 submissions (79%). Most (n 34, 72%)
ere conducted in a deterministic way; some were done in a prob-
Table 3 – Results of quality assessment for the pharmacoe
Topic Item
Objectives Explicit and clear
Perspective Explicit and clear
Type of evaluation Explicit and clear
Appropriate methodology
Target population Appropriateness of target popu
-correspondence with indica
Time horizon Enough to identify major healt
Comparator Justification of choice
Appropriateness of comparato
-comparisons with more tha
when needed
Data source Justification of selection proce
-search strategy, database
-inclusion and exclusion cri
-Clinical benefit estimation Appropriateness of data sourc
-unbiased clinical data from
-Cost estimation Explicit methodology to estim
-disaggregate analysis
Appropriateness of data sourc
-reliable and domestic sourc
-inclusive items and rationa
Health outcomes Appropriateness of health out
-final health outcome used
-strong relationship betwee
outcomes if the surrogate ou
Discounting Apply when needed
Model analysis‡ Transparency and appropriate
-explicit and feasible assum
Uncertainty evaluation Performance of sensitivity ana
Enough range to cover uncerta
Generalizability Justification of generalizability
population
Results Presentation of incremental co
Budget impact Suggestion of budget impact fo
-appropriate assumption an
Others Explicit justification of the stu
Total§
n  Number of relevant submissions.
%  Proportions were calculated by dividing the number of releva
sions.
* All submissions (n  47) that were assessed between June 2005 and
† Submissions in subgroup (n  34) were assessed between 2007 and
‡ Twenty submissions with modeling were submitted (11 submissio
lated by dividing the number of relevant submissions on the item
models.
§ “Total” accounts for the average compliance rate of all submissions
of “yes” responses by the total number of whole items composed obilistic way (n  3, 6%).Quality assessment of submissions
On average, 14 of the 20 items on the HIRA checklist developed
according to the PE guidelines were fulfilled (70.9%; range
35.0%–100%). In addition, the mean quality scores and the com-
pliance rate of the QHES checklist were 60.2 (range 30 –97) and
62.6% (range 31%–94%), respectively. The mean compliance rate
for all submissions and for submissions after the introduction
of the positive list system (70.9% and 73.1%, respectively) was
similar (Table 3).
Among 20 items on the HIRA checklist, 12 showing compli-
ance rates above 70% included the following: presentation of
mic evaluations according to the HIRA checklist.
All
submissions*
Subgroup†
n % n %
27 57 18 53
42 89 31 91
47 100 34 100
36 77 23 68
n 27 57 20 59
come 33 70 24 71
42 89 29 85
e main comparator
35 74 25 74
31 66 23 68
t patients
35 74 27 79
st 32 68 26 76
t item and estimation
hods
25 53 22 65
s
ogate and final health
e was used
42 89 30 88
35 74 32 94
of the analysis 7 35 5 45
37 79 27 79
s 29 62 19 56
e results to the target 22 47 19 56
fectiveness ratio 42 89 29 85
bursement
a
40 85 31 91
itations 13 28 11 32
47 71 34 73
bmissions on the individual items by the total number of submis-
ember 2009 were included in this study.
since the introduction of the positive list system.
ter introduction of the positive list system). Proportions were calcu-
the total number of applicable submissions assessed by submitted
bgroup. The compliance rate was calculated by dividing the number
HIRA checklist.cono
latio
tion
h out
r(s)
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ing when needed, sufficient consideration of uncertainty, pre-
sentation of ICERs, and suggestion of budget impact for reim-
bursement.
In contrast, other items with a compliance rate of less than 70%
included presentation of study objectives, appropriateness of the
target population, transparent processes to select clinical benefit
and cost data and a reasonable estimation of them, modeling
methods with feasible assumptions, consideration of generaliz-
ability, performance of sensitivity analysis with enough range to
cover uncertainty, and an explicit description of study limitations.
Among them, the target population in only 27 (57%) submissions
was identical with the reimbursed population. In addition, 25
(53%) conducted cost estimations as the PE guidelines recommend
by using national resource utilization and presenting them in a
disaggregate way. Furthermore, the PE guidelines request that the
estimating process and the modeling approach should be reported
transparently. Only 7 of the 20 submissions (35%), however, in
which a modeling approach was used presented analytic methods
enough to reproduce the analysis and performed it with appropri-
ate assumptions. In terms of generalizability, 22 (47%) justified the
generalizability between the results for the group analyzed in the
study and the national target population.
The role of PEs in decision making
The mean compliance rate of PEs with the PE guidelines were not
significantly different among coverage decisions (“recommended,”
“recommended with restricted use,” or “not recommended”); they
were 69.8% (range 35.0%–95%, n  23), 74.3% (range 40.0%–95.0%,
n 14), and 68.5% (range 40.0%– 100%, n 10), respectively.
The cost per QALY in the cost-utility analyses (n 17) fell in the
range from dominant to 59K USD analyzed from a societal per-
spective (n  13) and 1.4K to 14.4K USD from a payer perspective
(n  4). The ICERs of the base case along with uncertainty around
their estimations analyzed from the societal perspective (n  13)
are shown in Figure 1. These were done according to the Anatom-
ical Therapeutic Chemical classification, which was generated by
using the step1 (one-digit) code of the Anatomical Therapeutic
Chemical classification system released by the World Health Or-
ganization . Based on the ICERs of the base case, they varied from
dominant to 28K USD per QALY for “recommended” submissions
(n 6), from 8K to 20K USD per QALY for ones “recommended with
restricted use” (n 4), and from 13K to 59K USD per QALY for ones
that were “not recommended” (n  3).
Discussion
It has been 3 years since the reform of the pharmaceutical ben-
efit schedule, which resulted in PEs becoming an official re-
quirement in coverage decisions on newly introduced drugs.
There were some concerns, such as the lack of expertise, expe-
rience, and local data, to conduct PEs in the early stage of the
new system [22,23]. However, the 47 PEs that had been submit-
ted for coverage decisions addressed the overall quality level as
being approximately at 70% according to the HIRA checklist as-
sessment.
There is no universal and standard instrument for the quality
assessment of PEs submitted for coverage decisions. Most of the
quality assessment studies were previously conducted by using
checklists according to the guidelines developed by individual
countries. For the rational coverage decisions, HIRA also assessed
the quality level of the PEs submitted for reimbursement in accor-
dance with the PE guidelines in Korea. Besides using the HIRA
checklist, we tried to make direct comparisons between our study
and other studies by using the QHES checklist. dComparable material was evaluated by using the QHES check-
list, which was about quality assessment of PEs submitted to the
Pharmaceutical Benefit Board, the Swedish decision-making com-
mittee for medicines that is similar to the Drug Benefit Coverage
Assessment Committee in Korea. It showed a broadly similar qual-
ity level to our study (n  47, 63%, and n  20, 70%; Drug Benefit
overage Assessment Committee and Pharmaceutical Benefit
oard, respectively) in terms of the mean compliance rate with the
HES checklist [24]. In addition, there were several studies that
dentified the extent of compliance with their individual PE guide-
ines or with the QHES checklist. Although direct comparisons be-
ween the previous studies and our study were limited, because
ach of the results was generated for a specific disease area, such
s gastroesophageal reflux disease [21,25], or did not reflect the
ppraisals for reimbursement [16], their quality level was similar
o that of our study.
Several items with the lowest compliance rate, such as inap-
ropriateness of target population, cost estimation, and modeling
ethods with feasible assumptions, might result from the lack of
elevant evidence and resources, which has caused continuous
ontroversy about the uncertainty of the estimation [1,17]. Espe-
ially for cost estimation, this tendency looks similar even in Can-
da, which has been conducting PEs for over a decade, and where
here have been continuous problems regarding the lack of na-
ional statistics in terms of the availability of cost and resource
Fig. 1 – Ranked ICER per QALY including uncertainties for
the submissions that used cost-utility analysis from
societal perspectives. Bar (I) = Range of uncertainties by
sensitivity analysis. *Disease areas of health-care
interventions were presented by the Anatomical
Therapeutic Chemical (ATC) code. †The medicines that the
Health Insurance Review and Assessment Services (HIRA)
recommended to be listed according to the approved label
by the Korean Food and Drug Administration (KFDA). ‡The
medicines that HIRA recommended to be listed within the
limited range for the submitted drug, which was different
from those in a similar therapeutic class. §The medicines
that HIRA decided not to recommend. A (alimentary tract
and metabolism), B (blood and blood-forming organs), C
(cardiovascular system), G (genitourinary system and sex
hormones), H (systemic hormonal preparations, excluding
sex hormones and insulins), J (anti-infectives for systemic
use), L (antineoplastic and immunomodulating agents), N
(nervous system), R (respiratory system), S (sensory
organs), V (various). ICER, incremental cost-effectiveness
ratio; QALY, quality-adjusted life-year; USD, US dollar. (The
Korean won [KW] was converted at a rate of 1165 KW per
USD, which was the monthly average exchange rate in
December 2009.)ata [16]. In addition, the uncertainty of the PEs grows because of
e
e
o
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of the lack of relevant evidence to apply. And all these could affect
generalizability, which showed low compliance as well. As for
generalizability, efficacy data cited from clinical trials for model-
ing approaches were limited to reflect real-world effectiveness.
Also, data from clinical trials conducted in foreign countries were
difficult to apply directly to the local target population without
considering the differences in demographic characteristics of the
population, the treatment pattern for the disease, and differences
in the use of comparators. To solve this problem with lack of clin-
ical evidence and efforts to secure clinical evidence, the govern-
ment started conducting national clinical trials [26] and analyzing
the outcomes of health-care technologies [27]. These efforts could
be the starting point for solving the uncertainty issues around
cost-effectiveness for the reimbursement of pharmaceuticals and
make a solid base for evidence-based decision making.
The cost-effectiveness ratio has been considered one of the
major factors having a decisive effect on recommendations [28].
There are known ranges of cost-effectiveness that were retrospec-
tively drawn [3,29,30]. Most of the decision-making bodies, how-
ver, have no fixed ICER threshold, and they also consider the
xistence of other alternatives and innovations in health technol-
gies [31–34]. HIRA also considers cost-effectiveness as one ele-
ment among other decision criteria, including clinical benefit,
budget impact, reimbursement status in other countries, and
other features that may affect public health. Therefore, for assess-
ing cost-effectiveness, HIRA does not have a fixed ICER threshold.
Instead, it decided to consider the per capita GDP (26K USD, 2007
[35]) as a reference value and made flexible judgments based on
disease severity, societal burden, quality of life, and innovations. In
addition, HIRA has been trying to make coverage decisions consider-
ing the substantial range of uncertainty around cost-effectiveness,
which was similar to the previous decisions of the Common Drug
Review and the Pharmaceutical Benefits Advisory Committee that
the reimbursement rates were lower when there were considerable
clinical or economic uncertainties [1]. For instance, HIRA did not rec-
ommend the drug for recurrent stroke treatment presented as “B” in
Figure 1 for which the ICER of sensitivity analysis increased by 2
times compared with that around the per capita GDP of the base-case
analysis. On the contrary, it recommended listing the drug for met-
astatic breast cancer therapy (presented as “L” with an open bar
graph in Fig. 1), even though the ICER of the drug was higher than the
per capita GDP, because the drug satisfied the need of patients with
severe disease and showed solid cost-effectiveness with respect to
the range of uncertainty.
Generally, submissions with low-quality level were not recom-
mended because of high uncertainty of the results. In this study,
however, the overall quality level of PEs of drugs submitted for
reimbursement was 70.9% (mean, n  47), which was similar
among coverage decisions. Also, the overall ICER of the base-case
analysis tends to increase gradually according to the order of cov-
erage decisions (“recommended,” “recommended with restricted
use,” or “not recommended”). This shows that HIRA made coverage
decisions with the PEs that were adequate for decision making.
Therefore, individual decisions could be made by considering the
result of cost-effectiveness with uncertainty and the specified crite-
ria such as clinical benefit, budget impact, reimbursement status in
other countries, and the other features that may affect public health.
Further analysis, however, will be required as the number of decision
materials grows, because it was difficult to identify the factors that
affect the coverage decisions in depth because only 17 submissions
presented the ICER per QALY, a relatively small number. In addition,
the decision-making process applied to the PE submissions could be
different in details, because we improved the process consistently for
the stable and feasible implementation of the new system. This lim-
itation, however, may not a crucial flaw of this study, because theframework of the criteria was identical regardless of the applied pe-
riod.
Conclusions
This study was performed to assess PEs submitted for coverage
decision and to present the role of PEs in decision making for the
first time in Korea. Most of the submissions for coverage deci-
sions reached a level that was adequate for decision making by
HIRA. The overall barrier for conducting PEs was a lack of rele-
vant evidence to use. PEs with good quality submitted for cov-
erage decisions in Korea have played an important role for se-
lecting cost-effective drugs by providing useful information.
This study could be helpful for understanding the present state
of the PEs submitted for coverage decisions in Korea and could
be valuable for suggesting items that need to be improved to
have better appraisals.
Source of financial support: The authors have no other finan-
cial relationships to disclose.
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